SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?


To: aknahow who wrote (1185)12/2/1999 9:33:00 PM
From: William Partmann  Respond to of 1686
 
George, thanks for the news.

Bill



To: aknahow who wrote (1185)12/2/1999 10:25:00 PM
From: Mark Bong  Read Replies (1) | Respond to of 1686
 
Thanks George
Elise is the best Biotech analyst on Wall Street.
It sounds like BGEN's drug has better efficacy that the XOMA-Genentech drug. XOMA had 25% of its patients show an improvement of 75% or more. If BGEN had 23% show a 100% improvement, they should be ahead of the game. I do not know what the Enbrel data showed.